INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINE
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
PURPOSE: We evaluated the incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease. We also assessed the predictive role of bone turnover markers determined at baseline. MATERIALS AND METHODS: A total of 112 patients were consecutively enrolled in our study from July 1990 to July 1998 and followed until death or the last followup. Bone pain, disease extent in bone, serum prostate specific antigen, hemoglobin, and a panel of bone formation and resorption markers were assessed at baseline before any second line treatment. RESULTS: Skeletal complications in 34 patients (30.3%, estimated yearly incidence 12.3%) involved vertebral deformity or collapse requiring spinal orthosis in 20 (17.9%), spinal cord compression in 7 (6.2%), pathological bone fracture in 10 (8.9%), symptomatic hypercalcemia in 1 (0.9%) and symptomatic hypocalcemia in 1 (0.9%). Median time to the evidence of the initial skeletal complication was 9.5 months. These adverse events did not influence overall survival. At baseline patients with eventual skeletal complications had greater bone pain (p = 0.02), a heavier tumor load in bone (p = 0.005), lower performance status (p = 0.05), and higher serum alkaline phosphatase (p <0.02) and urinary deoxypyridoline (p <0.05) than their counterparts. Multivariate analysis revealed that only urinary deoxypyridinoline was independently associated with the onset of these events (p <0.02). The scatterplot of urinary deoxypyridinoline values in patients with and without skeletal complications enabled us to detect a cutoff of 38 pM./mM. for predicting 51% of skeletal events with only an 8% false-positive rate. CONCLUSIONS: Skeletal complications are common in patients with prostate cancer and hormone refractory disease. Bone loss is the major cause of onset. Baseline deoxypyridinoline at the cutoff point noted had moderate sensitivity but high specificity for predicting these adverse skeletal events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A common complication of prostate cancer is metastasis to the bone tissue, which occurs in about 10% of patients with primary disease and 80% of patients with advanced, late-stage disease (Berruti et al., 2000; Bubendorf et al., 2000).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Berruti et al., 2000
Citations
Cites
Nonparametric Statistics for the Behavioral Sciences
Guitton, H., & Siegel, S. (1958) · Revue économique · doi:10.2307/3498751 · Cited by 35,245
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Skeletal complications of malignancy
Coleman, R. E. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.0.co;2-g · Cited by 1,502
A computer program for comparing K samples with right-censored data
Lee, E. T., & Desu, M. M. (1972) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(72)90019-0 · Cited by 705
Hanson, D. A., Weis, M. A. E., Bollen, A.-M., Maslan, S. L., Singer, F. R., & Dr. Eyre, D. R. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650071119 · Cited by 656
Risteli, J., Elomaa, I., Niemi, S., Novamo, A., & Risteli, L. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.4.635 · Cited by 622
Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen
Melkko, J., Niemi, S., Risteli, L., & Risteli, J. (1990) · Clinical Chemistry · doi:10.1093/clinchem/36.7.1328 · Cited by 513
Guise, T. A., & Mundy, G. R. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0323 · Cited by 472
Molecular aspects of tumor cell invasion and metastasis
Aznavoorian, S. A., Murphy, A. N., Stetler‐Stevenson, W. G., & Liotta, L. A. (1993) · Cancer · doi:10.1002/1097-0142(19930215)71:4<1309::aid-cncr2820710423>3.0.co;2-m · Cited by 459
PROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
DANIELL, H. W., DUNN, S. R., FERGUSON, D. W., LOMAS, G., NIAZI, Z., & STRATTE, P. T. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)68000-7 · Cited by 452
Cited by
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
“Patients with hormone-refractory metastatic prostate cancer are particularly prone to incapacitating progressive bone disease ( 10 ).”
BackgroundCornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079
“Direct symptoms from advanced or metastatic cancer, for example, pain, hypercalcaemia, spinal cord compression, and pathological fractures, also affect health adversely [173,174].”
BackgroundLevitt, D., & Levitt, M. (2016) · International Journal of General Medicine · doi:10.2147/ijgm.s102819 · Cited by 763
Coleman, R. E., Major, P., Lipton, A., Brown, J. E., Lee, K.-A., Smith, M., Saad, F., Zheng, M., Hei, Y. J., Seaman, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.091 · Cited by 533
Weinfurt, K. P., Li, Y., Castel, L. D., Saad, F., Timbie, J. W., Glendenning, G. A., & Schulman, K. A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi122 · Cited by 362
Skeletal Fractures Negatively Correlate With Overall Survival in Men With Prostate Cancer
Oefelein, M. G., Ricchiuti, V., Conrad, W., & Resnick, M. I. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64561-2 · Cited by 347
Rosen, L. S., Gordon, D. H., Dugan, W., Major, P., Eisenberg, P. D., Provencher, L., Kaminski, M., Simeone, J., Seaman, J., Chen, B., et al. (2004) · Cancer · doi:10.1002/cncr.11892 · Cited by 335
“Recent evidence suggests that osteoblastic lesions also have a strong lytic component, as evidenced by dramatic elevation of bone resorption markers.(8) –10 Therefore, a recently completed comparative trial of zoledronic acid versus pamidronate in patients with advanced breast carcinoma included patients with osteolyt…”
BackgroundBERRUTI, A., DOGLIOTTI, L., TERRONE, C., CERUTTI, S., ISAIA, G., TARABUZZI, R., REIMONDO, G., MARI, M., ARDISSONE, P., DE LUCA, S., et al. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64985-3 · Cited by 315
Self-citationExercise for men with prostate cancer: a systematic review and meta-analysis
Bourke, L., Smith, D., Steed, L., Hooper, R., Carter, A., Catto, J., Albertsen, P. C., Tombal, B., Payne, H. A., & Rosario, D. J. (2016) · European Urology · doi:10.1016/j.eururo.2015.10.047 · Cited by 300
Halvorson, K. G., Kubota, K., Sevcik, M. A., Lindsay, T. H., Sotillo, J. E., Ghilardi, J. R., Rosol, T. J., Boustany, L., Shelton, D. L., & Mantyh, P. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0826 · Cited by 222
“( 24 ). Whereas tumor metastasis to bone is common in lung, breast, and prostate cancers, prostate cancer is unique in that bone is often the only clinically detectable site of metastasis and prostate tumors tend to be primarily bone-forming rather than bonedestroying (25, 26).”
BackgroundPathological Sprouting of Adult Nociceptors in Chronic Prostate Cancer-Induced Bone Pain
Jimenez-Andrade, J. M., Bloom, A. P., Stake, J. I., Mantyh, W. G., Taylor, R. N., Freeman, K. T., Ghilardi, J. R., Kuskowski, M. A., & Mantyh, P. W. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3300-10.2010 · Cited by 212
“Once prostate cancer cells have metastasized to the skeleton, tumor-induced bone pain frequently follows (Berruti et al., 2000; Dy et al., 2008).”
BackgroundInfluentialVan den Brande, R., MJ Cornips, E., Peeters, M., Ost, P., Billiet, C., & Van de Kelft, E. (2022) · Journal of Bone Oncology · doi:10.1016/j.jbo.2022.100446 · Cited by 204
“…2002-2013 2.221 417 8 50 187,8 3,6 19,2 22,5 119,9 4/5 4 Prostate carcinoma Kuban 1986 [36] Retrospective cohort, Virginia US, 1975-1983 611 / 41 / / 67,1 / / / 4/5 4 Berruti 2000 [37] Prospective cohort, Italy, 1990-1998 / 112 7 10 / / 62,5 / 89,3 4/5 3 Loblaw 2003 † [24] Retrospective…”
InfluentialSurgical Management of Metastatic Bone Disease
Bickels, J., Dadia, S., & Lidar, Z. (2009) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/jbjs.h.00175 · Cited by 203
OEFELEIN, M. G., RICCHUITI, V., CONRAD, W., SEFTEL, A., BODNER, D., GOLDMAN, H., & RESNICK, M. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65661-3 · Cited by 188
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
Nilsson, S., Cislo, P., Sartor, O., Vogelzang, N. J., Coleman, R. E., O'Sullivan, J. M., Reuning-Scherer, J., Shan, M., Zhan, L., & Parker, C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw065 · Cited by 182
Lipton, A., Small, E., Saad, F., Gleason, D., Gordon, D., Smith, M., Rosen, L., Ortu Kowalski, M., Reitsma, D., & Seaman, J. (2002) · Cancer Investigation · doi:10.1081/cnv-120014886 · Cited by 175
“These patients are at risk for vertebral deformity or collapse, spinal cord compression, and pathologic fractures.([7])”
BackgroundCathepsin K mRNA and Protein Expression in Prostate Cancer Progression
Brubaker, K., Vessella, R., True, L., Thomas, R., & Corey, E. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.2.222 · Cited by 162
Hall, C. L., Dai, J., van Golen, K. L., Keller, E. T., & Long, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1544 · Cited by 159
“Patients with osseous lesions of prostate cancer display breakdown products of collagen I within their blood and urine, specifically deoxypyridinoline, type I collagen cross-linked C-telopeptide, and type 1 procollagen C-propeptide ( 42 ).”
BackgroundDePuy, V., Anstrom, K. J., Castel, L. D., Schulman, K. A., Weinfurt, K. P., & Fred Saad, C. (2007) · Supportive Care in Cancer · doi:10.1007/s00520-006-0203-x · Cited by 144
“Skeletal-related events (SREs), such as pathologic fractures and spinal cord compression, are major causes of morbidity in patients with prostate cancer and can lead to other comorbidities including pain [3, 18].”
BackgroundNelson, J. B., Nabulsi, A. A., Vogelzang, N. J., Breul, J., Zonnenberg, B. A., Daliani, D., Schulman, C. C., & Carducci, M. A. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000042162.08938.27 · Cited by 138
Low bone mineral density in hormone-na�ve men with prostate carcinoma
Smith, M. R., McGovern, F. J., Fallon, M. A., Schoenfeld, D., Kantoff, P. W., & Finkelstein, J. S. (2001) · Cancer · doi:10.1002/1097-0142(20010615)91:12<2238::aid-cncr1254>3.0.co;2-2 · Cited by 137
“study, 30% of men with prostate carcinoma and bone metastases experienced an adverse skeletal event during the course of their disease.(30) The most common adverse skeletal event (53% of all events) was vertebral body deformity or collapse.”
BackgroundCosts of Prostate Cancer, Metastatic to the Bone, in The Netherlands
Groot, M. T., Kruger, C. G. G. B., Pelger, R. C. M., & Groot, C. A. U. (2003) · European Urology · doi:10.1016/s0302-2838(03)00007-1 · Cited by 134
Oades, G. M., Senaratne, S. G., Clarke, I., Kirby, R. S., & Colston, K. W. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000070685.34760.5f · Cited by 132
The role of tumor microenvironment in prostate cancer bone metastasis
Morrissey, C., & Vessella, R. L. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21214 · Cited by 109
“Increased bone resorption is also a prognostic factor for skeletal-related events in metastatic PCa [Berruti et al., 2000].”
BackgroundLiu, D., Kuai, Y., Zhu, R., Zhou, C., Tao, Y., Han, W., & Chen, Q. (2020) · Scientific Reports · doi:10.1038/s41598-020-64073-6 · Cited by 110
Barlev, A. (2010) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2010.16.9.693 · Cited by 101
Osteoporosis during androgen deprivation therapy for prostate cancer
Smith, M. R. (2002) · Urology · doi:10.1016/s0090-4295(02)01579-0 · Cited by 102
METABOLIC BONE DISEASE INDUCED BY PROSTATE CANCER: RATIONALE FOR THE USE OF BISPHOSPHONATES
Berruti, A., Dogliotti, L., Tucci, M., Tarabuzzi, R., Fontana, D., & Angeli, A. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65498-5 · Cited by 107
Self-citationSmith, H. S. (2011) · Pain Physician · doi:10.36076/ppj.2011/14/e373 · Cited by 108
Prognostic value of serum markers for prostate cancer
Stenman, U., Abrahamsson, P., Aus, G., Lilja, H. G., Bangma, C., Hamdy, F. C., BOCCON-GIBOD, L., & Ekman, P. (2005) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/03008880510030941 · Cited by 107
“[97] Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, et al.”
BackgroundAssessment of therapeutic response in patients with metastatic bone disease
Clamp, A. R., Danson, S. J., Nguyen, H. D., Cole, D. E. C., & Clemons, M. J. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01596-7 · Cited by 95
Natural History and Treatment of Bone Complications in Prostate Cancer
Fred Saad, C., Clarke, N. W., & Colombel, M. C. (2006) · European Urology · doi:10.1016/j.eururo.2005.12.045 · Cited by 97
“Additionally, recent evidence has revealed that levels of bone resorption correlate with bone pain intensity and the risk of skeletal complications in patients with prostate cancer [83] and significantly correlatewith disease state [84–88], clinical outcome [53,89,90], and likelihood of imminent death [91].”
BackgroundInfluentialAR function in promoting metastatic prostate cancer
Augello, M. A., Den, R. B., & Knudsen, K. E. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9471-3 · Cited by 88
“PCa primarily metastasizes to bone, where tumor growth leads to high fracture rates and is associated with patient morbidity [44, 45].”
Treatment and prevention of bone complications from prostate cancer
Lee, R. J., Saylor, P. J., & Smith, M. R. (2010) · Bone · doi:10.1016/j.bone.2010.05.038 · Cited by 100
“Increased osteoclast activity is independently associated with risk for subsequent skeletal complications, disease progression, and death [5,20].”
BackgroundFeldman, L., Wang, Y., Rhim, J. S., Bhattacharya, N., Loda, M. F., & Sytkowski, A. J. (2005) · The Prostate · doi:10.1002/pros.20310 · Cited by 91
Galectin-3 Inhibits Osteoblast Differentiation through Notch Signaling
Nakajima, K., Kho, D. H., Yanagawa, T., Harazono, Y., Gao, X., Hogan, V. A., & Raz, A. (2014) · Neoplasia · doi:10.1016/j.neo.2014.09.005 · Cited by 91
“005 Introduction Patients with malignant prostate and breast cancer are often afflicted by bone metastasis [1,2].”
BackgroundCremers, S., & Garnero, P. (2006) · Drugs · doi:10.2165/00003495-200666160-00001 · Cited by 95
Bone Microenvironment Modulates Expression and Activity of Cathepsin B in Prostate Cancer
Podgorski, I., Linebaugh, B. E., Sameni, M., Jedeszko, C., Bhagat, S., Cher, M. L., & Sloane, B. F. (2005) · Neoplasia · doi:10.1593/neo.04349 · Cited by 85
Radiotherapy for Oligometastases and Oligo-Recurrence of Bone in Prostate Cancer
Tabata, K., Niibe, Y., Satoh, T., Tsumura, H., Ikeda, M., Minamida, S., Fujita, T., Ishii, D., Iwamura, M., Hayakawa, K., et al. (2012) · Pulmonary Medicine · doi:10.1155/2012/541656 · Cited by 68
“Skeletal-related events (SREs), such as pathological fractures and spinal cord compression, are major causes of morbidity in patients with prostate cancer and may lead to other comorbidities including pain [1, 2].”
BackgroundNordstrand, A., Ylitalo, E. B., Thysell, E., Jernberg, E., Crnalic, S., Widmark, A., Bergh, A. R. J., Lerner, U. H., & Wikström, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041223 · Cited by 67
“This classification, however, is probably oversimplified, as prostate cancer metastases in addition to increased bone formation also show dysregulated bone resorption [10,12,13].”
BackgroundRole of Bisphosphonates in Prostate Cancer
Fred Saad, C., & Schulman, C. C. (2003) · European Urology · doi:10.1016/j.eururo.2003.10.003 · Cited by 66
Berruti, A., Tucci, M., Mosca, A., Tarabuzzi, R., Gorzegno, G., Terrone, C., Vana, F., Lamanna, G., Tampellini, M., Porpiglia, F., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602767 · Cited by 64
“In a previous publication on the first 112 cases (Berruti et al, 2000), we identified several predictive factors, including serum alkaline phosphatase (ALP), urinary deoxy-pyridinoline and disease extent (DE) in bone.”
BackgroundSelf-citationCytotoxicity and enzyme inhibition studies of polyoxometalates and their chitosan nanoassemblies
Shah, H. S., Al‐Oweini, R., Haider, A., Kortz, U., & Iqbal, J. (2014) · Toxicology Reports · doi:10.1016/j.toxrep.2014.06.001 · Cited by 64
“Alkaline phosphatase level usually rises in colon, breast, lung, thyroid and prostate cancer when it metastasizes to bone and liver [57-62].”
BackgroundAdjei, I. M., Sharma, B., Peetla, C., & Labhasetwar, V. D. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.019 · Cited by 63
“At later stages of prostate cancer, there is gross metastasis to the bones involving the ribs, sternum, and long bones [4, 63, 64].”
Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response
Klusa, D., Lohaus, F., Furesi, G., Rauner, M., Benešová, M., Krause, M., Kurth, I., & Peitzsch, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.627379 · Cited by 64
Kinnane, N. (2007) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2007.07.002 · Cited by 62
Michaelson, M. D., Marujo, R. M., & Smith, M. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0735 · Cited by 60
Raman Spectroscopy in Prostate Cancer: Techniques, Applications and Advancements
Gaba, F., Tipping, W. J., Salji, M. J., Faulds, K., Graham, D., & Leung, H. Y. (2022) · Cancers · doi:10.3390/cancers14061535 · Cited by 63
Beebe‐Dimmer, J., Cetin, K., Shahinian, V. B., Morgenstern, H., Yee, C. L., Schwartz, K., & Acquavella, J. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2258 · Cited by 60
Reed, S. D., Radeva, J. I., Glendenning, G. A., Fred Saad, C., & Schulman, K. A. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000116777.94426.60 · Cited by 59
Management of Vertebral Metastases in Prostate Cancer: A Retrospective Analysis in 119 Patients
Cereceda, L. E., Fléchon, A., & Droz, J. (2003) · Clinical Prostate Cancer · doi:10.3816/cgc.2003.n.010 · Cited by 56
Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment
Eaton, C. L., & Coleman, R. E. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00071-9 · Cited by 60
Population-based study on use of chemotherapy in men with castration resistant prostate cancer
Lissbrant, I. F., Garmo, H., Widmark, A., & Stattin, P. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.770164 · Cited by 56
The potential role of bisphosphonates in prostate cancer
Oades, G. M., Coxon, J. P., & Colston, K. W. (2002) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500607 · Cited by 52
Inoue, T., Segawa, T., Kamba, T., Yoshimura, K., Nakamura, E., Nishiyama, H., Ito, N., Kamoto, T., Habuchi, T., & Ogawa, O. (2009) · Urology · doi:10.1016/j.urology.2008.07.062 · Cited by 51
Fred Saad, C. (2002) · Clinical Prostate Cancer · doi:10.3816/cgc.2002.n.016 · Cited by 50
Metastatic Prostate Cancer: Complications and Treatment
McMurtry, C. T., & McMurtry, J. M. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51367.x · Cited by 45
Paracrine sonic hedgehog signalling by prostate cancer cells induces osteoblast differentiation
Zunich, S. M., Douglas, T., Valdovinos, M., Chang, T., BUSHMAN, W. A., Walterhouse, D. O., Iannaccone, P. M., & Lamm, M. L. G. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-12 · Cited by 45
“Complications from skeletal metastasis result in a dramatic reduction in the patient's quality of life and invariably lead to death [2,3].”
A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation
Lin, S.-H., Cheng, C.-J., Lee, Y.-C., Ye, X., Tsai, W.-W., Kim, J. H., Pasqualini, R., Arap, W., Navone, N. M., Tu, S.-M., et al. (2008) · Oncogene · doi:10.1038/onc.2008.156 · Cited by 44
“Prostate cancer bone metastases are characterized by their ability to induce osteoblastic lesions and localized bone formation (Berruti et al., 2000).”
BackgroundVijayaraghavalu, S., Gao, Y., Rahman, M. T., Rozic, R., Sharifi, N., Midura, R. J., & Labhasetwar, V. D. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119558 · Cited by 43
“Consequences of bone metastasis are often devastating; it affects bone remodeling, causes bone pain, fractures and nerve compression, and is the primary cause of prostate and breast cancer-related morbidity and mortality [8].”
BackgroundLacerna, L. V., & Hohneker, J. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.017 · Cited by 43
Tucci, M., Mosca, A., Lamanna, G., Porpiglia, F., Terzolo, M., Vana, F., Cracco, C. M., Russo, L. M., Gorzegno, G., Tampellini, M., et al. (2008) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2008.10 · Cited by 42
“8 However, they are more frequent when the tumor become refractory to hormone manipulations.”
Self-citationSmith, H. S., & Barkin, R. L. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3182456dff · Cited by 44
Michaelson, M. D., Kaufman, D. S., Kantoff, P. W., Oh, W. K., & Smith, M. R. (2006) · Cancer · doi:10.1002/cncr.22043 · Cited by 41
“Elevated biochemical markers of osteoblast and osteoclast activity are associated with greater risk of skeletal complications, disease progression, and death in men with hormone-refractory metastatic prostate cancer.(2,3) Serial measurements of bone turnover markers may provide a convenient method for evaluating the e…”
BackgroundBisphosphonate therapy in the oncology setting
Lipton, A. (2003) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.8.2.469 · Cited by 41
“Patients with prostate cancer (> 500,000 cases globally each year) often experience incapacitating bone pain from progressive bone disease, which occurs in 65 – 75% of patients, with a median survival of 12 – 53 months after diagnosis of bone metastases [6,8,9].”
BackgroundBone markers and current laboratory assays
Hannon, R. A., & Eastell, R. (2006) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(06)80003-4 · Cited by 40
Meulenbeld, H. J., van Werkhoven, E. D., Coenen, J. L., Creemers, G. J. M., Loosveld, O. J. L., de Jong, P. C., ten Tije, A. J., Fosså, S. D., Polée, M., Gerritsen, W. R., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.014 · Cited by 36
Morrissey, C. M., Kostenuik, P. J., Brown, L. G., Vessella, R. L., & Corey, E. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-148 · Cited by 36
“Increased bone resorption is also a prognostic factor for skeletal-related events in metastatic CaP [9].”
BackgroundWeiss, R. J., Forsberg, J. A., & Wedin, R. (2011) · Acta Orthopaedica · doi:10.3109/17453674.2011.645197 · Cited by 36
“Advances in the treatment of prostate cancer have extended life expectancy (Berruti et al. 2000, Carlin and Andriole 2000, Saad et al. 2006).”
BackgroundMiyaji, Y., Saika, T., Yamamoto, Y., Kusaka, N., Arata, R., Ebara, S., Nasu, Y., Tsushima, T., & Kumon, H. (2004) · Urology · doi:10.1016/j.urology.2004.03.012 · Cited by 36
Biology and clinical management of prostate cancer bone metastasis
Ye, X.-C., Choueiri, M., Tu, S.-M., & Lin, S.-H. (2007) · Frontiers in bioscience · doi:10.2741/2311 · Cited by 40
“The major factor affecting quality of life is bone pain; other concerns include anemia, nerve compression, and pathological fractures (10).”
BackgroundBiochemical Markers of Bone Metabolism
Cremers, S., Garnero, P., & Seibel, M. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00020-3 · Cited by 57
O’Sullivan, J. M., Carles, J., Cathomas, R. L., Iturriaga, A. G., Heinrich, D. A., Kramer, G., Ost, P., van Oort, I. M., & TOMBAL, B. F. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.02.007 · Cited by 34
Zoledronic acid for the treatment of prostate cancer
Finianos, A. N., & Aragon‐Ching, J. B. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1574754 · Cited by 35
“Bony lesions in prostate cancer are typically mixed between excessive bone formation by osteoblasts (ostebloastic) and increased osteoclastic activities [4,9,55,56].”
BackgroundThe impact of osteoporosis in men treated for prostate cancer
Oefelein, M. G., & Resnick, M. I. (2004) · Urologic Clinics of North America · doi:10.1016/j.ucl.2004.02.002 · Cited by 31
Role of the Bone Microenvironment in the Development of Painful Complications of Skeletal Metastases
Park, S. H., Eber, M. R., Widner, D. B., & Shiozawa, Y. (2018) · Cancers · doi:10.3390/cancers10050141 · Cited by 33
“A full 80% of patients with bone metastases have CIBP [3].”
BackgroundZolochevska, O., Díaz‐Quiñones, A. O., Ellis, J., & Figueiredo, M. L. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24265 · Cited by 29
“…of bone lesions associated with prostate cancer include increased immature bone formation (Berruti et al., 2000), and also an increase in osteoclast-mediated osteolysis (Goltzman, 1997; Mundy and Guise, 1997; Boyce et al., 1999), resulting in a high level of bone resorption (Berruti et al., 2001).”
BackgroundBerruti, A., Dogliotti, L., Tucci, M., Tarabuzzi, R., Guercio, S., TORTA, M., Tampellini, M., Dovio, A., Poggio, M., Scarpa, R. M., et al. (2002) · The International Journal of Biological Markers · doi:10.5301/jbm.2008.2194 · Cited by 28
Self-citationProstate Cancer and Bone Metastases: Medical Treatment
Clark, P. E., & Torti, F. M. (2003) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000093840.72468.e1 · Cited by 27
“Nevertheless, there also is an abnormal elevation in overall osteoclastic activity in the bones of patients with advanced or metastatic prostate cancer.(5,6,13,15,16,31,32,72) Therefore, although the risk of fracture may be lower than for patients with osteolytic metastases, pathologic fractures can and do occur.”
BackgroundInfluentialAsahi, H., Mizokami, A., Miwa, S., Keller, E. T., Koshida, K., & Namiki, M. (2006) · International Journal of Urology · doi:10.1111/j.1442-2042.2006.01360.x · Cited by 27
“Management of bone metastases which cause pathological fracture, nerve paralysis and movement restrictions is very important for improvement and maintenance of patient's quality of life and prognosis (6-8).”
BackgroundLiu, R., Su, S., Xing, J., Liu, K., Zhao, Y., Stangis, M. M., Jacho, D., Yildirim-Ayan, E. D., Gatto-Weis, C. M., Chen, B., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02849-0 · Cited by 28
“Up to 90% of patients with advanced-stage PCa develop bone metastases, but only 10% are diagnosed with bone metastases at initial diagnosis [2-4].”
BackgroundInterleukin-27 Gene Delivery for Modifying Malignant Interactions Between Prostate Tumor and Bone
Zolochevska, O., Ellis, J., Parelkar, S. S., Chan‐Seng, D., Emrick, T. S., Wei, J., Patrikeev, I., Motamedi, M., & Figueiredo, M. L. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.091 · Cited by 26
“The types of bone lesions associated with prostate cancer include increased immature bone formation (osteoblastic lesions) (Berruti et al., 2000), and also enhanced osteolysis by osteoclasts (OC; osteoclastic lesions) (Goltzman, 1997; Mundy and Guise, 1997; Boyce et al., 1999), which promote a high…”
Generali, D., Dovio, A., Tampellini, M., Tucci, M., Tedoldi, S., TORTA, M., Bonardi, S., Allevi, G., Aguggini, S., Milani, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604390 · Cited by 26
“Bone pain was evaluated at baseline and before each ZA administration (i.e., after 28, 56 and 84 days) using a validated pain questionnaire, as previously reported (Berruti et al, 2000).”
MethodSelf-citationRosen, L. S., Harland, S. J., & Oosterlinck, W. (2002) · American Journal of Clinical Oncology · doi:10.1097/00000421-200212001-00004 · Cited by 26
“In patients with hormone-refractory prostate cancer, metastatic bone disease causes vertebral deformity or collapse, spinal cord compression, or pathologic bone fracture, with a median onset of only 10 months.(5) Bone lesions are characterized on the basis of their radiologic appearance as osteolytic, osteoblastic (os…”
BackgroundBisphosphonates in the Management of Metastatic Prostate Cancer
Heidenreich, A. (2003) · Oncology · doi:10.1159/000072485 · Cited by 25
Rodrigues, P. R. T., Hering, F., & Campagnari, J. C. (2004) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500752 · Cited by 25
Smith, H. S., & Mohsin, I. (2013) · The Korean journal of pain · doi:10.3344/kjp.2013.26.3.223 · Cited by 32
“75-90% of patients with metastatic or advanced stage cancer experiencing significant cancer-induced pain [1-5].”
BackgroundFokkema, M., de Heide, L. J. M., van Schelven, W. D., & Hamdy, N. A. T. (2005) · PubMed · Cited by 25
The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases
Lechner, B., DeAngelis, C., Jamal, N., Emmenegger, U., Pulenzas, N., Giotis, A., Sheehan, P., Tsao, M. N., Bedard, G., & Chow, E. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2142-2 · Cited by 24
“In contrast, low incidences of hypocalcemia compared with our results have been found in a study of prostate cancer patients with bone metastases and castrate-resistant disease [15].”
BackgroundResultBisphosphonates to Prevent Skeletal Complications in Men With Metastatic Prostate Cancer
Smith, M. R. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000095102.34708.bc · Cited by 24
New model for the induction of osteoblastic bone metastases in rat.
Liepe, K., Geidel, H., Haase, M., Hakenberg, O. W., Runge, R., & Kotzerke, J. (2005) · PubMed · Cited by 24
Hussain, A., Lee, R. J., Graff, J. N., & Halabi, S. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.04.020 · Cited by 26
Clinical Aspects of Bone Metastases in Prostate Cancer
Tu, S., & Lin, S.-H. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-9129-4_2 · Cited by 24
Novel agents in the management of castration resistant prostate cancer
Garcia, J., & Chaturvedi, S. (2014) · Journal of Carcinogenesis · doi:10.4103/1477-3163.128185 · Cited by 24
“57-59] Thus, prevention and management of bone metastases and SREs is a priority to reduce PCa related morbidity and mortality.”
Crosstalk between bone metastatic cancer cells and sensory nerves in bone metastatic progression
Park, S. H., Tsuzuki, S., Contino, K. F., Ollodart, J., Eber, M. R., Yu, Y., Steele, L. R., Inaba, H., Kamata, Y., Kimura, T., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202302041 · Cited by 20
“A full 80% of patients with bone metastases have CIBP (Berruti et al, 2000), and it often presents as their fi rst symptom.”
Contemporary Therapeutic Approaches Targeting Bone Complications in Prostate Cancer
Lee, R. J., Saylor, P. J., & Smith, M. R. (2010) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2010.n.005 · Cited by 24
Hypocalcaemia following denosumab in prostate cancer: A clinical review
Lau, L., Cliff, E. R. S., Wong, V., Wong, H., Torkamani, N., Eer, A., Weickhardt, A. J., & Grossmann, M. (2020) · Clinical Endocrinology · doi:10.1111/cen.14169 · Cited by 20
“4, and marked elevations in baseline alkaline phosphatase (ALP), 1,348 IU/L [normal range 30-110], and in procollagen type 1 N propeptide (P1NP), >1200 mcg/L [15-80], with pre-existing borderline hypocalcaemia (total calcium 2.”
BackgroundWu, Y., Peng, S., Cheng, B., Zhong, H., Cen, M., Fu, J., Luo, T., Guo, Z., Lai, Y., & Huang, H. W. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.100905 · Cited by 19
“Bone metastases are the most frequent site of distant metastasis, accounting for over 80% of cases[3, 4].”
BackgroundBackground to and Management of Treatment-Related Bone Loss in Prostate Cancer
Berruti, A., Tucci, M., Terrone, C., Gorzegno, G., Scarpa, R. M., Angeli, A., & Dogliotti, L. (2002) · Drugs & Aging · doi:10.2165/00002512-200219120-00002 · Cited by 19
Self-citationPolascik, T. J. (2007) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4501019 · Cited by 18
Metadata
- Authors
- BERRUTI, A., DOGLIOTTI, L., BITOSSI, R., FASOLIS, G., GORZEGNO, G., BELLINA, M., TORTA, M., PORPIGLIA, F., FONTANA, D., & ANGELI, A.
- Affiliations
- Ospedale San Luigi Gonzaga (IT)
- Venue
- Journal of Urology
- Published
- 2000-10
- Volume
- 164
- Issue
- 4
- Pages
- 1248-1253
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2159622173
- Cited by
- 212
- References
- 33
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 2 · 2016: 6 · 2015: 8 · 2014: 9 · 2013: 8 · 2012: 10
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Journal of Urology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Keywords
- skeletal complications, bone metastatic prostate cancer, castration-resistant prostate cancer, bone turnover markers, urinary deoxypyridinoline, bone resorption, bone formation, pathological fracture, spinal cord compression, vertebral collapse, alkaline phosphatase, predictive biomarkers, bone pain
- MeSH terms
- Aged, Aged, 80 and over, Alkaline Phosphatase, Amino Acids, Bone Neoplasms, Bone Resorption, Calcium, Evaluation Studies as Topic, Humans, Male, Middle Aged, Prostatic Neoplasms, Regression Analysis, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.